

# ESMO PRECEPTORSHIP PROGRAMME NON-SMALL-CELL LUNG CANCER

Standards of care, evolving paradigm and future perspectives

**Singapore**  
**10-11 January 2023**

**CO-CHAIRS** Pasi A. Jänne, United States  
Tony S. K. Mok, Hong Kong  
Solange Peters, Switzerland

**SPEAKERS** Maximilian Diehn, United States  
Rafal Dziadziuszko, Poland  
Keith M. Kerr, United Kingdom  
Se-Hoon Lee, Republic of Korea  
Natasha Leigh, Canada  
Tetsuya Mitsudomi, Japan  
Antonio Passaro, Italy  
David Planchard, France  
Daniel S. W. Tan, Singapore  
Junko Tanizaki, Japan  
Pan-Chyr Yang, Taiwan

## LEARNING OBJECTIVES

- To learn about best clinical practice in the management of Non-Small-Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic setting
- To understand the importance of pathology, histo-prognostic and molecular factors and liquid biopsies in the management of NSCLC
- To learn about the management of patients after progression, side effects of treatments and the use of targeted agents in NSCLC and obtain some highlights of ongoing clinical research

## Tuesday, 10 January 2023

09:00-09:10 10'	Opening and welcome	Tony S. K. Mok, HK Solange Peters, CH
10'	Introduction and objectives	
09:10-10:05 55'	<b>SESSION 1</b> Screening, diagnosis and staging	Chair: Solange Peters, CH
20'	Early detection of lung cancer: Biology, screening and cost-effectiveness	Pan-Chyr Yang, KR
20'	The role of pathology and genetic/molecular analyses	Keith M. Kerr, UK
15'	Discussion	Faculty

10:05-10:35	Coffee break	
10:35-11:30 55'	<b>SESSION 2</b> Adjuvant therapy	Chair: Tony S. K. Mok, HK
20'	Adjuvant/Neo-adjuvant chemotherapy and radiotherapy strategies for resected NSCLC	Natasha Leighl, CA
20'	Adjuvant and neo-adjuvant targeted and immunotherapeutic agents: clinical evidence and clinical research	Daniel S. W. Tan, SG
15'	Discussion	Faculty
11:30-12:10 40'	<b>SESSION 3</b> Multi-disciplinary lung tumour board	Chair: Pasi A. Jänne, US
40'	Management of stage III - Case presentation <ul style="list-style-type: none"> <li>- Surgeon's point of view</li> <li>- Radiotherapist's point of view</li> <li>- Medical oncologist's point of view</li> <li>- Discussion</li> </ul>	Tetsuya Mitsudomi, JP Rafal Dziadziuszko, PL Antonio Passaro, IT
12:10-12:50 40'	<b>SESSION 4</b> Multi-disciplinary lung tumour board	Chair: Solange Peters, CH
40'	Management of oligometastatic disease - Case presentation <ul style="list-style-type: none"> <li>- Surgeon's point of view</li> <li>- Radiotherapist's point of view</li> <li>- Medical oncologist's point of view</li> <li>- Discussion</li> </ul>	Tetsuya Mitsudomi, JP Rafal Dziadziuszko, PL Tony S. K. Mok, HK
12:50-13:50	Lunch	
13:50-14:50 60'	<b>SESSION 5</b> Audience cases	Chair: Tony S. K. Mok, HK
60'	Participants clinical case discussion (6x10')	Faculty
14:50-15:20	Coffee break	
15:20-16:15 55'	<b>SESSION 6</b> Systemic therapy for advanced NSCLC	Chair: Tony S. K. Mok, HK
20'	Immune Checkpoint Inhibitors as a consolidation in stage III NSCLC	Se-Hoon Lee, KR
20'	Immune Checkpoint Inhibitors across lines of metastatic NSCLC	Solange Peters, CH
15'	Discussion	Faculty
17:00	Networking cocktail reception	

## Wednesday, 11 January 2023

<b>08:30-10:25</b> <b>115'</b>	<b>SESSION 7</b> <b>Targeted therapies</b>	<b>Chair:</b> <b>Solange Peters, CH</b>
20'	Systemic therapy for non-oncogene addicted NSCLC	Natasha Leighl, CA
20'	New treatment options for EGFR-mutated NSCLC	Tony S. K. Mok, HK
20'	New treatment options for ALK-ROS1 rearranged NSCLC	David Planchard, FR
20'	KRAS mutant NSCLC	Pasi A. Jänne, US
20'	RET/TRK/BRAF/MET	Antonio Passaro, IT
15'	Discussion	Faculty
<b>10:25-10:55</b>	<b>Coffee break</b>	
<b>10:55-11:25</b> <b>30'</b>	<b>SESSION 8</b> <b>Audience cases</b>	<b>Chairs:</b> <b>Tony S. K. Mok, HK</b>
30'	Participants clinical case discussion (3x10')	Faculty
<b>11:25-13:00</b> <b>95'</b>	<b>SESSION 9</b> <b>Other thoracic tumours and molecular testing</b>	<b>Chair:</b> <b>Pasi A. Jänne, US</b>
20'	Optimal platform and sequence for biomarker testing in advanced NSCLC: IHC, PCR, NGS and more	Keith M. Kerr, UK
20'	Liquid biopsy applications in the early detection and management of NSCLC patients	Maximilian Diehn, US
20'	Immunotherapy for SCLC	Junko Tanizaki, JP
20'	Immunotherapy for mesothelioma	Rafal Dziadziuszko, PL
15'	Discussion	Faculty
<b>13:00-13:10</b> <b>10'</b>	<b>Conclusion and take home messages</b>	<b>Pasi A. Jänne, US</b> <b>Tony S. K. Mok, HK</b> <b>Solange Peters, CH</b>
<b>13:10-14:10</b>	<b>Lunch</b>	

**Note:** Each 10-minute slot for clinical case discussion includes a 5' case presentation and 5' Q&A / panel discussion